In last trading session, Puma Biotechnology Inc (NASDAQ:PBYI) saw 1.33 million shares changing hands with its beta currently measuring 1.09. Company’s recent per share price level of $2.71 trading at -$0.9 or -24.79% at ring of the bell on the day assigns it a market valuation of $133.17M. That closing price of PBYI’s stock is at a discount of -185.24% from its 52-week high price of $7.73 and is indicating a premium of 21.4% from its 52-week low price of $2.13. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.46 million shares which gives us an average trading volume of 481.27K if we extend that period to 3-months.
For Puma Biotechnology Inc (PBYI), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 3.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0.33 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Puma Biotechnology Inc (NASDAQ:PBYI) trade information
Upright in the red during last session for losing -24.79%, in the last five days PBYI remained trading in the red while hitting it’s week-highest on Thursday, 08/08/24 when the stock touched $2.71 price level, adding 30.15% to its value on the day. Puma Biotechnology Inc’s shares saw a change of -37.30% in year-to-date performance and have moved -27.21% in past 5-day. Puma Biotechnology Inc (NASDAQ:PBYI) showed a performance of -31.27% in past 30-days. Number of shares sold short was 3.82 million shares which calculate 10.12 days to cover the short interests.
Puma Biotechnology Inc (PBYI) estimates and forecasts
Statistics highlight that Puma Biotechnology Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -56.28% of value to its shares in past 6 months, showing an annual growth rate of -37.31% while that of industry is 17.50. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. This year revenue growth is estimated to fall -7.50% from the last financial year’s standing.
2 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 70.65M for the same. And 2 analysts are in estimates of company making revenue of 55.45M in the next quarter. Company posted 56.1M and 72.2M of sales in current and next quarters respectively a year earlier.
Puma Biotechnology Inc (NASDAQ:PBYI)’s Major holders
Insiders are in possession of 15.32% of company’s total shares while institution are holding 73.59 percent of that, with stock having share float percentage of 86.90%. Investors also watch the number of corporate investors in a company very closely, which is 73.59% institutions for Puma Biotechnology Inc that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at PBYI for having 3.49 million shares of worth $18.5 million. And as of 2024-03-31, it was holding 7.3345 of the company’s outstanding shares.
The second largest institutional holder is MILLENNIUM MANAGEMENT LLC, which was holding about 3.17 million shares on 2024-03-31. The number of shares represents firm’s hold over 6.6543 of outstanding shares, having a total worth of $16.79 million.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Mar 31, 2024 , the former fund manager was holding 1.27 shares of worth $3.45 million or 2.59% of the total outstanding shares. The later fund manager was in possession of 908.45 shares on Jun 30, 2024 , making its stake of worth around $2.47 million in the company or a holder of 1.85% of company’s stock.
